AR050155A1 - 3-aminoindazoles, un procedimiento de preparcion, uso de los compuestos para preparar medicamentos, dichos medicamentos y un compuesto intermediario - Google Patents
3-aminoindazoles, un procedimiento de preparcion, uso de los compuestos para preparar medicamentos, dichos medicamentos y un compuesto intermediarioInfo
- Publication number
- AR050155A1 AR050155A1 ARP050102033A ARP050102033A AR050155A1 AR 050155 A1 AR050155 A1 AR 050155A1 AR P050102033 A ARP050102033 A AR P050102033A AR P050102033 A ARP050102033 A AR P050102033A AR 050155 A1 AR050155 A1 AR 050155A1
- Authority
- AR
- Argentina
- Prior art keywords
- mono
- hal
- het
- trisubstituted
- con
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Los 3-aminoindazoles de la formula (1), son inhibidores de la SGK y pueden ser utilizados para el tratamiento de enfermedades y dolencias causadas por las SGK y tales como diabetes, obesidad, síndrome metabolico (dislipidemia), hipertonía sistémica y pulmonar, enfermedades cardiocirculatorias y renales, en general para todo tipo de fibrosis y procesos inflamatorios. Se reivindica el compuesto, un método de preparacion, su uso para preparar medicamentos y un kid para el compuesto y un compuesto intermediario de síntesis. Reivindicacion 1: Compuestos de la formula (1), en donde: W es -[C(R2)2]n-, -[C(R2)2]nCONR2[C(R2)2]n-, -[C(R2)2]nCONR2NR2[C(R2)2]n-, -[C(R2)2]nNR2CO[C(R2)2]n-, -[C(R2)2]nNR2CO[C(R2)2]nNR2-, -[C(R2)2]nO[C(R2)2]n-, - [C(R2)2]nNR2[C(R2)2]n-, -[C(R2)2]nN[C(R2)2R1][C(R2)2]n-, -[C(R2)2]nO[C(R2)2]nCONR2[C(R2)2]n-, -[C(R2)2]nNR2[C(R2)2]nCONR2[C(R2)2]n-, -[C(R2)2]nNR2COO[C(R2)2]n-, -[C(R2)2]nCO[C(R2)2]n-, -[C(R2)2]nCOO[C(R2)2]n-, -C(R2)=C(R29CONR2[C(R2)2]n o -C(R2)=N- NR2CO[C(R2)2]n; X es H, Hal, A, OR2, N(R2)2, NO2, CN, COOR2, CON(R2)2, NR2COA, NR2SO2A, CO2 o SO2NR2; R1 es un carbociclo o heterociclo saturado o insaturado mono o bicíclico con 0 a 4 átomos de N, O y/o S, que puede estar mono, bi o trisustituido con R2, Hal, A, -[C(R3)2]n-Ar, -[C(R3)2]n-Het, -O-[C(R3)2]n-Het, -[C(R3)2]n-cicloalquilo, OR2, N(R2)2, NO2, CN, -[C(R2)2]nCOOR2, O-[C(R2)2]nCOOR2, -[C(R2)2]nCON(R2)2, -[C(R2)2]nCONR2N(R2)2, O-[C(R2)2]oCON(R2)2, O-[C(R2)2]oCONR2N(R2)2, NR2COA, NR2CON(R2)2, NR2SO2A, COR2, SO2NR2, S(O)mA, =S, =NR3 y/u =O (oxígeno del carbonilo); R2 es H, A, -[C(R3)2]n-Ar', -[C(R3)2]n-Het', -[C(R3)2]n-cicloalquilo, -[C(R3)2]n-OR3, -[C(R3)2]n-COOA o -[C(R3)2]nN(R3)2; R3 es H o A; A es alquilo no ramificado o ramificado con C1-10, en donde uno o dos grupos CH2 pueden estar reemplazados por átomos de O o S y/o por grupos -CH=CH- y/o también 1-7 átomos de H pueden estar reemplazados por F; Ar es fenilo, naftilo o bifenilo insustituido o mono, di o trisustituido con Hal, A, OR2, N(R2)2, NO2, CN, COOR2, CON(R2)2, NR2COA, NR2CON(R2)2, NR2SO2A, COR2, SO2N(R2)2, S(O)mA, -[C(R3)2]n-COOR2 u -O[C(R3)2]o-COOR2; Ar' es fenilo, naftilo o bifenilo insustituido o mono, di o trisustituido con Hal, A, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3CON(R3)2, NR3SO2A, COR3, SO2N(R3)2, S(O)mA, -[C(R3)2]n-COOR3 u -O[C(R3)2]o-COOR3; Het es un heterociclo saturado o insaturado mono o bicíclico con 1 a 4 átomos de N, O y/o S, que puede estar mono, bi o trisustituido con R2, Hal, A, -[C(R3)2]n-Ar, -[C(R3)2]n-Het, -[C(R3)2]n-cicloalquilo, OR2, N(R2)2, NO2, CN, -[C(R2)2]nCOOR2, O--[C(R2)2]nCOOR2, -[C(R2)2]nCON(R2)2, -[C(R2)2]nCONR2N(R2)2, O-[C(R2)2]oCON(R2)2, O-[C(R2)2]oCONR2N(R2)2, NR2COA, NR2CON(R2)2, NR2SO2A, COR2, SO2NR2, S(O)MA y/u =O (oxígeno del carbonilo); Het' es un heterociclo saturado o insaturado mono o bicíclico con 1 a 4 átomos de N, O y/o S, que puede estar mono, bi o trisustituido con R3, Hal, A, OR2, N(R3)2, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3SO2A, COR3, SO2NR3, S(O)mA, =S, =NR3 y/u =O (oxígeno del carbonilo), Hal es F, Cl, Br o I; m es 0, 1 o 2; n es 0, 1, 2, 3 o 4; o es 1, 2 o 3; así como sus derivados, sales, solvatos y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004028862A DE102004028862A1 (de) | 2004-06-15 | 2004-06-15 | 3-Aminoindazole |
Publications (1)
Publication Number | Publication Date |
---|---|
AR050155A1 true AR050155A1 (es) | 2006-10-04 |
Family
ID=35455063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102033A AR050155A1 (es) | 2004-06-15 | 2005-05-18 | 3-aminoindazoles, un procedimiento de preparcion, uso de los compuestos para preparar medicamentos, dichos medicamentos y un compuesto intermediario |
Country Status (10)
Country | Link |
---|---|
US (1) | US7872039B2 (es) |
EP (1) | EP1765788B1 (es) |
JP (1) | JP5128939B2 (es) |
AR (1) | AR050155A1 (es) |
AT (1) | ATE432924T1 (es) |
AU (1) | AU2005254617B2 (es) |
CA (1) | CA2570264C (es) |
DE (2) | DE102004028862A1 (es) |
ES (1) | ES2326897T3 (es) |
WO (1) | WO2005123688A2 (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6180731A (ja) * | 1984-09-28 | 1986-04-24 | Toshiba Corp | 管球の製造方法 |
DE102004051277A1 (de) * | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
DE102006005179A1 (de) * | 2006-02-06 | 2007-08-09 | Merck Patent Gmbh | Aminoindazolderivate |
DE102006005180A1 (de) * | 2006-02-06 | 2007-08-09 | Merck Patent Gmbh | Indazol-heteroaryl-derivate |
JP5255559B2 (ja) * | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
EP2044018A1 (en) | 2006-07-11 | 2009-04-08 | Pfizer Japan, Inc. | Substituted n-bicyclicalkyl bicyclic carboxyamide compounds |
DE102006033140A1 (de) | 2006-07-18 | 2008-01-24 | Merck Patent Gmbh | Aminoindazolharnstoffderivate |
TW200829578A (en) | 2006-11-23 | 2008-07-16 | Astrazeneca Ab | Chemical compounds 537 |
JO2754B1 (en) | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
WO2008079073A1 (en) * | 2006-12-22 | 2008-07-03 | Astrazeneca Ab | Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders |
DE102007002717A1 (de) * | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
DE102007022565A1 (de) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
RU2487873C2 (ru) * | 2007-06-08 | 2013-07-20 | Эбботт Лэборетриз | 5-замещенные индазолы в качестве ингибиторов киназы |
US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
WO2009133831A1 (ja) | 2008-04-28 | 2009-11-05 | 旭化成ファーマ株式会社 | フェニルプロピオン酸誘導体及びその用途 |
US20100080786A1 (en) | 2008-05-20 | 2010-04-01 | Markus Berger | Phenyl or Pyridinyl Substituted Indazoles Derivatives |
ES2548141T3 (es) | 2008-11-20 | 2015-10-14 | Glaxosmithkline Llc | Compuestos químicos |
EP2382197B1 (en) * | 2008-12-30 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
JP2012521429A (ja) * | 2009-03-23 | 2012-09-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛治療用のp2x3受容体アンタゴニスト |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
AT509045B1 (de) | 2010-01-29 | 2011-06-15 | Planta Naturstoffe Vertriebsges M B H | Verbindungen zur behandlung von asthma bronchiale |
CA2786314A1 (en) * | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
KR20130006664A (ko) * | 2010-03-16 | 2013-01-17 | 다나-파버 캔서 인스티튜트 인크. | 인다졸 화합물 및 그의 용도 |
JP2013525438A (ja) * | 2010-04-29 | 2013-06-20 | アメリカ合衆国 | ヒトピルビン酸キナーゼ活性剤 |
PE20140011A1 (es) | 2010-09-03 | 2014-01-31 | Forma Tm Llc | Compuestos y composiciones novedosos para la inhibicion de nampt |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
AU2012300317B2 (en) * | 2011-08-26 | 2016-12-01 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
CN104080455B (zh) | 2011-09-14 | 2018-07-31 | 润新生物公司 | 某些化学实体、组合物及方法 |
JP5827849B2 (ja) * | 2011-09-20 | 2015-12-02 | サノフイ | N−[4−(1H−ピラゾロ[3,4−b]ピラジン−6−イル)−フェニル]−スルホンアミド及び薬剤としてのその使用 |
CA2856291C (en) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
US9670180B2 (en) | 2012-01-25 | 2017-06-06 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
JP6154887B2 (ja) * | 2012-03-20 | 2017-06-28 | セラゴン ファーマシューティカルズ,インク. | エストロゲン受容体モジュレーターおよびその使用 |
EP2897618B1 (en) | 2012-09-24 | 2021-11-17 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
WO2014063068A1 (en) | 2012-10-18 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
WO2014075077A1 (en) | 2012-11-12 | 2014-05-15 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
TW201427658A (zh) | 2012-12-10 | 2014-07-16 | Merck Sharp & Dohme | 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法 |
TWI644899B (zh) | 2013-02-04 | 2018-12-21 | 健生藥品公司 | Flap調節劑 |
EP3070085B1 (en) | 2013-02-04 | 2019-01-09 | Janssen Pharmaceutica NV | Flap modulators |
EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
EP3057955B1 (en) | 2013-10-18 | 2018-04-11 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
EP3097091A1 (en) * | 2014-01-24 | 2016-11-30 | AbbVie Inc. | 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
KR101731624B1 (ko) | 2014-07-01 | 2017-05-04 | 광주과학기술원 | 세포 리프로그래밍 유도용 조성물 |
WO2016105528A2 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
JP6861166B2 (ja) | 2015-03-27 | 2021-04-21 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
WO2016161571A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Indazole and azaindazole btk inhibitors |
CN106279119B (zh) * | 2015-05-27 | 2020-06-16 | 上海海和药物研究开发有限公司 | 一种新型激酶抑制剂的制备及其应用 |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
AU2016319125B2 (en) | 2015-09-09 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
DE102015012050A1 (de) * | 2015-09-15 | 2017-03-16 | Merck Patent Gmbh | Verbindungen als ASIC-Inhibitoren und deren Verwendungen |
SG11201901355SA (en) | 2016-08-30 | 2019-03-28 | Regeneron Pharma | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling |
JOP20190053A1 (ar) | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
CA3033249A1 (en) * | 2016-09-23 | 2018-03-29 | Novartis Ag | Indazole compounds for use in tendon and/or ligament injuries |
EP3529278A1 (en) | 2016-10-20 | 2019-08-28 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
CA3072103A1 (en) | 2017-08-21 | 2019-02-28 | Microbiotix, Inc. | Metabolically stable n-acylaminooxadiazoles useful as antibacterial agents |
EP3672620A1 (en) | 2017-08-22 | 2020-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of treating urea cycle disorders by interfering with glucagon receptor signaling |
EP3543231A1 (en) * | 2018-03-19 | 2019-09-25 | ETH Zurich | Compounds for treating cns- and neurodegenerative diseases |
WO2021007477A1 (en) | 2019-07-11 | 2021-01-14 | E-Scape Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2971842A (en) * | 1956-03-21 | 1961-02-14 | Gen Aniline & Film Corp | Light sensitive layers for photomechanical reproduction |
US2996467A (en) * | 1957-03-04 | 1961-08-15 | Dow Chemical Co | Asphalt-oil-rubber composition |
DE1280878B (de) * | 1961-11-30 | 1968-10-24 | Smith Kline French Lab | 3-Aminoindazole |
PE20020451A1 (es) * | 2000-09-15 | 2002-06-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de cinasa proteina |
US20030114448A1 (en) * | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
WO2003051847A1 (en) * | 2001-12-19 | 2003-06-26 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
ES2411655T3 (es) * | 2002-05-17 | 2013-07-08 | Pfizer Italia S.R.L. | Derivados de aminoindazol activos como inhibidores de quinasas, procedimiento para su preparación y composiciones farmacéuticas que los comprenden |
CA2497351C (fr) * | 2002-09-05 | 2012-08-21 | Aventis Pharma S.A. | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant |
EP1562935B1 (de) * | 2002-10-28 | 2006-09-06 | Bayer HealthCare AG | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren |
EP1638941B1 (en) * | 2003-05-22 | 2010-06-02 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
US7297709B2 (en) * | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
US7560467B2 (en) * | 2003-06-19 | 2009-07-14 | Smithkline Beecham Corporation | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors |
SE0301906D0 (sv) * | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
JP2007500700A (ja) * | 2003-07-29 | 2007-01-18 | スミスクライン ビーチャム コーポレーション | 化合物 |
-
2004
- 2004-06-15 DE DE102004028862A patent/DE102004028862A1/de not_active Withdrawn
-
2005
- 2005-04-04 DE DE502005007427T patent/DE502005007427D1/de active Active
- 2005-04-04 US US11/629,504 patent/US7872039B2/en not_active Expired - Fee Related
- 2005-04-04 ES ES05729376T patent/ES2326897T3/es active Active
- 2005-04-04 JP JP2007515792A patent/JP5128939B2/ja not_active Expired - Fee Related
- 2005-04-04 WO PCT/EP2005/003513 patent/WO2005123688A2/de active Application Filing
- 2005-04-04 EP EP05729376A patent/EP1765788B1/de active Active
- 2005-04-04 AU AU2005254617A patent/AU2005254617B2/en not_active Ceased
- 2005-04-04 CA CA2570264A patent/CA2570264C/en not_active Expired - Fee Related
- 2005-04-04 AT AT05729376T patent/ATE432924T1/de not_active IP Right Cessation
- 2005-05-18 AR ARP050102033A patent/AR050155A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1765788B1 (de) | 2009-06-03 |
JP2008502610A (ja) | 2008-01-31 |
ES2326897T3 (es) | 2009-10-21 |
WO2005123688A3 (de) | 2006-02-23 |
DE502005007427D1 (de) | 2009-07-16 |
US20070232620A1 (en) | 2007-10-04 |
US7872039B2 (en) | 2011-01-18 |
CA2570264C (en) | 2013-06-25 |
ATE432924T1 (de) | 2009-06-15 |
AU2005254617B2 (en) | 2011-05-26 |
AU2005254617A1 (en) | 2005-12-29 |
DE102004028862A1 (de) | 2005-12-29 |
EP1765788A2 (de) | 2007-03-28 |
JP5128939B2 (ja) | 2013-01-23 |
WO2005123688A2 (de) | 2005-12-29 |
CA2570264A1 (en) | 2005-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR050155A1 (es) | 3-aminoindazoles, un procedimiento de preparcion, uso de los compuestos para preparar medicamentos, dichos medicamentos y un compuesto intermediario | |
AR049502A1 (es) | Derivados de carbonilo heterociclicos | |
JP7248750B2 (ja) | オピオイド受容体リガンド並びにそれらの使用方法及び製造方法 | |
AU2016371600B2 (en) | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | |
KR101472248B1 (ko) | 뒤시엔느 근이영양증의 치료 | |
CA2789484C (en) | Cdc7 kinase inhibitors and uses thereof | |
AR059488A1 (es) | Hidrazidas de acido mandelico | |
US6410533B1 (en) | Antibacterial compounds | |
NO20085169L (no) | Krystallinske solvater og komplekser av (1S)-1,5-anhydro-L-C- (3-((fenyl)metyl)fenyl)-D-glucitol derivater med aminosyrer som SGLT2-inhibitorer for behandling av diabetes | |
AR043832A1 (es) | Compuestos de carbonilo y proceso de preparacion de los mismos | |
RU2010126105A (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства | |
EP2238110B1 (fr) | Dérivés de 5.6-bisaryl-2-pyr1dine-carboxamide, leur préparatio leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii | |
AR061374A1 (es) | Derivados de diamidas de acido antranilico con sus sustituyentes heteroaromaticos y heterociclicos | |
AR068730A1 (es) | Compuestos de diaril 1,2,4-oxadiazol,composiciones farmaceuticas que los contienen,proceso de preparacion y uso de los mismos como agentes inmunosupresores en el tratamiento de enfermedades autoinmunes y/o inflamatorias cronicas. | |
AR072792A1 (es) | DERIVADOS DE PIRROLOPIRIDINILPIRIMIDIN-2-IL-AMINA, PROCEDIMIENTO DE PREPARACIoN Y COMPOSICIONES FARMACEUTICAS | |
CA3010326C (en) | Sulfonamide derivative and preparation method and use thereof | |
PE20091692A1 (es) | Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
TWI812739B (zh) | Nadph氧化酶抑制劑、含其的醫藥組合物、及其應用 | |
AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina | |
AU2021202309A1 (en) | Novel catechol derivatives and pharmaceutical composition comprising the same | |
NZ203798A (en) | Olefinic benzimidazole derivatives and pharmaceutical formulations | |
AR042115A1 (es) | Amidas de acido carboxilico | |
AR048716A1 (es) | Derivados de acido pentenoico, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas | |
JP6695361B2 (ja) | 重水素化チエノピペリジン誘導体、調製方法、及びその使用 | |
US20030171379A1 (en) | Methods of treating, preventing, or inhibiting inflammation with Mactanamide compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |